sarcoidosis%20-%20pulmonary
SARCOIDOSIS - PULMONARY
Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.

Follow Up

General Surveillance Principles

  • Sarcoidosis patients should be monitored regularly
  • Monitoring should include a review of symptoms, physical exam, CXR & lung function tests
    • Perform other tests as necessary based on organ involvement
  • Monitor & treat patients for complications of sarcoidosis & related conditions (eg aspergilloma, osteoporosis, hypercalcemia, hypercalciuria)
  • Patients who have undergone therapy should be monitored for 3 years after cessation of treatment
  • Intermittent monitoring (every 3-6 months) is recommended for patients on TNF-alpha inhibitor therapy

Monitoring Intervals Based on Disease Stage

Stage 1

  • Initially every 6 months then once a year if stable

Stage 2, 3, 4

  • Initially every 3-6 months; monitor indefinitely

Serious extrapulmonary involvement, regardless of radiographic stage

  • Monitor indefinitely
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 21 Nov 2018
Use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA) and inhaled corticosteroid (ICS) leads to a reduced rate of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) and better lung function and health-related quality of life compared with dual therapy (ICS and LABA or LAMA and LABA) or LAMA monotherapy, according to the results of a meta-analysis.